Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10139897 | 0.83 | MEN1 (0.46) | MEN1KMT2AALDH1A1MAPTAKR1C3 | |
| SCHEMBL13284248 | 0.75 | MAPT (0.40) | MEN1KMT2AALDH1A1MAPTAKR1C3 | |
| SCHEMBL404730 | 0.73 | ERBB2 (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL409117 | 0.73 | MAPT (0.45) | MAPTAKR1C3HTR6HMOX1 | |
| SCHEMBL403561 | 0.73 | MAPT (0.50) | MAPTAKR1C3AKR1C1AKR1C2GBA1 | |
| SCHEMBL409007 | 0.71 | MAPT (0.48) | KMT2AALDH1A1MAPTHTR6 | |
| SCHEMBL2808596 | 0.68 | MEN1 (0.45) | MEN1KMT2AALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL10726996 | 0.68 | ALDH1A1 (0.86) | MEN1KMT2AALDH1A1MMP2GBA1 | |
| SCHEMBL848429 | 0.67 | KMT2A (0.73) | MEN1KMT2AALDH1A1AKR1C3AKR1C1 | |
| SCHEMBL409053 | 0.67 | PKM (0.47) | MEN1KMT2AALDH1A1MAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | claimed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | MEN1 3463/4885KMT2A 1887/4885ALDH1A1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.